Effects of medical plants from Zingiberaceae family on cardiovascular risk factors of type 2 diabetes mellitus: A systematic review and meta‐analysis of randomized controlled trials. Issue 7 (25th March 2022)

• Record Type: Journal Article
• Authors: Zhang, Xiaofeng; Chen, Xiaoli; Tang, Yujun; Guan, Xiaoxian; Deng, Jinlan; Fan, Jianming
• Is Part Of: Journal of food biochemistry. Volume 46:Issue 7(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-03-25
• Subjects: cardiovascular risk -- medical plants -- meta‐analysis -- systematic review -- type 2 diabetes mellitus -- Zingiberaceae; Food -- Analysis -- Periodicals; Food -- Composition -- Periodicals; Biochemistry -- Periodicals; 664.024
• DOI: 10.1111/jfbc.14130
• Languages: English
• ISSNs: 0145-8884

Abstract

Abstract: We performed a meta‐analysis on randomized controlled trials (RCTs) to evaluate the efficacy of Zingiberaceae on cardiovascular risk factors in type 2 diabetes mellitus (T2DM). PubMed, Web of Science, Embase, The Cochrane Library, and Scopus were searched systematically until October 18, 2021. Thirty‐four RCTs with 2154 patients met our inclusion. Pooled analysis indicated that Zingiberaceae can significantly improve body weight (BW) (WMD = −1.012, 95% CI: −1.673, −0.351, p = .003), fasting blood glucose (FBG) (WMD = −14.292, 95% CI: −18.588, −9.995, p < .001), glycosylated hemoglobin 1c (HbA1c) (WMD = −0.432, 95% CI: −0.607, −0.257, p < .001), serum insulin (WMD = −2.036, 95% CI: −2.857, −1.216, p < .001), homeostasis model assessment insulin resistance (HOMA‐IR) (WMD = −0.886, 95% CI: −1.375, −0.398, p < .001), high density lipoprotein‐cholesterol (HDL‐C) (WMD = 0.850, 95% CI: 0.018, 1.682, p = .045), triglyceride (TG) (WMD = −17.636, 95% CI: −27.121, −8.151, p < .001), diastolic blood pressure (DBP) (WMD = −0.642, 95% CI: −1.148, −0.137, p = .013), C‐reactive protein (CRP) (WMD = −0.623, 95% CI: −1.061, −0.186, p = .005), tumor necrosis factor‐α (TNF‐α) (WMD = −3.020, 95% CI: −4.327, −1.712, p < .001), and interleukin 6 (IL‐6) (WMD = −1.147, 95% CI: −1.887, −0.406, p = .002). The supplementation of Zingiberaceae may be an effective adjunctive therapy in management of T2DM and prevention cardiovascular complications by decreasing BW, improving blood glucose control, insulin resistance, lipid profiles (HDL‐C and TG), blood pressure (DBP), and reducing inflammation (CRP, TNF‐α, and IL‐6). Practical applications: Approximately half of the deaths of individuals with diabetes mellitus (DM) are attributable to cardiovascular disease (CVD), and individuals with T2DM have a two‐fold increased risk of cardiovascular mortality than healthy individuals. Currently, T2DM is mainly treated with hypoglycemic medication such as sulfonylureas, thiazolidinediones, meglitinides, and biguanides. Nevertheless, most of them with long‐term usage could cause side effects, including hypoglycemia and gastrointestinal troubles. Several species of the Zingiberaceae family are used in traditional herbal medicines, which have been widely used in traditional and complementary medicine. Proving the potential benefits of Zingiberaceae on T2DM and its cardiovascular complications has positive clinical implications for the use of this practical herb. Abstract : The supplementation of the Zingiberaceae plants may be an effective adjunctive therapy in management of T2DM and prevention its cardiovascular complications by decreasing BW, improving blood glucose control, insulin resistance, lipid profiles (HDL‐C and TG), blood pressure (DBP) and reducing inflammation (CRP, TNF‐α, and IL‐6).